0001193125-26-327014
SEC filing营收增长23%至$3.9B,净利大增,但主要受Community Living业务出售的一次性收益驱动。
| 指标 | 本期 | 去年同期 | 同比 |
|---|---|---|---|
| Revenue | $3,873.1M | $3,147.7M | +23.0% |
| Gross Profit | $492.7M | $374.9M | +31.5% |
| Gross Margin | 12.7% | 11.9% | +80 bps |
| Operating Income | $130.4M | $48.6M | +168.5% |
| Operating Margin | 3.4% | 1.5% | +190 bps |
| Net Income | $86.6M | $8.5M | +$78.1M |
| Diluted EPS | $0.39 | $0.04 | +$0.35 |
| Adjusted EBITDA | $205.5M | $142.5M | +44.2% |
| Operating Cash Flow | $166.9M | $150.7M | +10.7% |
| Free Cash Flow | $116.3M | $108.6M | +7.1% |
本季度营收增长23.0%至$3.9B,主要由Pharmacy Solutions部门增长22.1%驱动,其中Specialty and Infusion Pharmacy营收增长30.1%,得益于特定专科品牌药物的处方量增加。Provider Services部门营收增长30.3%,主要受Amedisys and LHC Branches收购贡献$77.9M。
毛利率提升80 bps至12.7%,主要由于Pharmacy Solutions部门毛利率从8.4%提升至8.8%,受益于产品组合向Specialty and Infusion Pharmacy倾斜。经营利润率大幅提升190 bps至3.4%,主要由于营收增长带来的经营杠杆效应。
净利大幅增长至$86.6M,但需注意其中包含出售Community Living业务的一次性税前收益$101.9M。剔除该收益后,核心盈利能力仍显著增强,Adjusted EBITDA增长44.2%至$205.5M,表明主营业务盈利能力持续改善。
| 分部 | 营收 | 同比 | 经营利润 | 利润率 | 驱动 |
|---|---|---|---|---|---|
| Pharmacy Solutions | $3,407.2M | +22.1% | $154.6M | 4.5% | Specialty and Infusion Pharmacy增长30.1% |
| Provider Services | $466.0M | +30.3% | $66.1M | 14.2% | Amedisys收购贡献$77.9M,有机增长$30.5M |
| 项目 | 本期 | 上期/变化 |
|---|---|---|
| Cash & ST investments | $550.4M | +$462.0M |
| Total Debt | $2,249.3M | -$320.5M |
| Operating Cash Flow | $166.9M | +$16.2M |
| Capex | $50.6M | +$8.5M |
| Free Cash Flow | $116.3M | +$7.7M |
公司杠杆率从2.99x降至2.15x,主要由于出售Community Living业务获得$810.9M现金,并偿还$300M债务。现金余额大幅增加至$550.4M,流动性充裕。
资本配置:
一次性异常项:
主要风险:
关注点: